<DOC>
	<DOCNO>NCT00685698</DOCNO>
	<brief_summary>Safety Efficacy Study TG-873870 ( Nemonoxacin ) Diabetic Foot Infections</brief_summary>
	<brief_title>Safety Efficacy Study TG-873870 ( Nemonoxacin ) Diabetic Foot Infections</brief_title>
	<detailed_description>This study ass safety efficacy TG-873870 ( Nemonoxacin ) patient Diabetic Foot Infections . Pharmacokinetic ( PK ) pharmacodynamic ( PD ) assessment conduct subgroup eight consent patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Focal Infection</mesh_term>
	<criteria>Body weight ≥ 40 kg Previously know newly diagnose diabetes mellitus , include type 1 type 2 ( per American Diabetes Association guideline ) , control proper lifestyle ( diet , exercise ) treatment either oral medication insulin Patients ' HbA1c ≦ 12 % screen Clinically define diabetic foot infection mild moderate severity ( PEDIS grade 23 ) base guideline Infectious Diseases Society America . It include inframalleolar infection softtissue , paronychia , cellulitis , myositis , abscess , tendonitis Evidence necrotic tissue , purulent collection abscess may require excision , incision drainage ( base investigator 's judgment , surgeon need ) Must able provide suitable tissue specimen ( preferably obtain biopsy tissue curettage , purulent fluid aspiration , rather swab ) infect wound ( appropriate cleansing debridement ) Gramstaining bacterial culture ( aerobes anaerobe ) A confirm Grampositive pathogen infection Gramstain . The criterion determine patient 's eligibility study recruitment Gramstained smear least 1 Grampositive organism see least two high power field . A solely Grampositive pathogen infection polymicrobial infection include Grampositive Gramnegative pathogens acceptable within framework study A comorbid disease condition could compromise evaluation participation study , severe hepatic disease ( e.g. , active hepatitis , decompensated liver cirrhosis ) , renal failure ( estimate creatinine clearance [ CrCl ] &lt; 30 ml/minute need hemodialysis peritoneal dialysis ) , active systemic malignancy ( advanced metastatic ) , unless enrollment deem appropriate discretion Investigator prior consultation study Medical Monitor History prolong QTc interval medical condition require use concomitant medication associate increase QTc interval ( e.g. , class I class III antiarrhythmic agent ) Contact dermatitis infect skin area , infect thirddegree burn wound , necrotizing fascitis , extensive gangrene , pyoderma gangrenosum , deep vein thrombosis , shock , medical disorder could either interfere evaluation treatment response patient therapy Radiological evidence bone joint infection within 7 day prior screen , i.e . potential osteomyelitis septic arthritis Clinically define uninfected severe infection ( PEDIS grade 1 4 ) base Infectious Diseases Society America classification system Any know severe immunosuppressive condition , active hematological malignancy , HIV infection active treatment immunosuppressive drug ( include corticosteroid dose &gt; 20 mg/day prednisone , equivalent ) Has receive receive chemotherapy oncolytics within six month prior enter study History current active alcohol abuse ( &gt; 3 drink daily binge drinking ) illicit drug use Known suspect critical ischemia affect limb ( base investigator ' clinical judgment vascular assessment ) Wound contains proximate prosthetic material device is/are schedule removal Patient foot infection , investigator 's judgment , severe enough require hospitalization intravenous antibiotic therapy Neutrophil count &lt; 1000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Diabetic Foot Infections , DFI , Nemonoxacin</keyword>
</DOC>